Amgen

Gilead Sciences

Vertex Pharmaceuticals

Regeneron Pharmaceuticals

IQVIA Hlds

Illumina

Natera

Biogen

ICON

Alnylam Pharmaceuticals

VanEck Vectors Biotech ETF

BBH tracks a market-cap-weighted index of the 25 largest biotech firms globally.

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

November has been a big month for stock and biotech ETFs, and with the Federal Aviation Administration announcing that it supported the “first mass air shipment” of coronavirus vaccines on Friday, pharmaceutical companies and airlines are now readying networks for wide dissemination, which could be a further boon for biotech ETFs. United Airlines ferried Pfizer's much-touted [.

How Will Vaccine Arrivals Affect Biotech ETFs?

Loncar Cancer Immunotherapy ETF

Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has been some debate as to exactly when the vaccines will be available however.

Biotech ETFs Remain Hot As Investors Await Upcoming Vaccine

The COVID-19 pandemic has given way to new technological innovations in the biotechnology sector with respect to creating a vaccine. ETF investors looking for a play that can take them well into 2021 might find the VanEck Vectors® Biotech ETF (BBH) appealing.

Bullish on Biotech? The BBH ETF is Not Just a 2020 Play

Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech, Moderna, is anticipated to release key data shortly from a late-stage trial, that will reveal whether its Covid-19 vaccine is efficacious.

Will Moderna Vaccine News Boost Biotech ETFs?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

How Will Biotech ETFs React to These Q3 Earnings Release?

ARK Genomic Revolution Multi-Sector ETF

First Trust NYSE Arca Biotechnology Index Fund

As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, which are already garnering interest as 2020 winds down.

Can't Get Enough Biotech Exposure in Your Portfolio?

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoon, on track for its biggest daily gain in nearly three weeks.

Biotech ETFs at multi-week highs, extending winning streak

Invesco Dynamic Biotechnology & Genome ETF

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Biotech ETFs to Shine on Coronavirus Antibodies Progress

The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Top-Performing Biotech ETFs Amid the Coronavirus Crisis

Biotech Sector Chart The broad stock market’s two day rally saw biotech stocks surge higher. In particular, the reversal in Biotech Sector ETFs BBH and XBI looks to be bullish.

Biotech Sector ETF Reversal Higher Triggers Buy Signal

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.

How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

VanEck Vectors Pharmaceutical ETF

For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.

A Divergence Has Occurred In Healthcare

Principal Healthcare Innovators Index ETF

Amplify Treatments Testing & Advancements ETF

iShares Genomics Immunology and Healthcare ETF

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creating optimism for a swifter economic recovery. Shares of the now notorious biotech gained 6% in trading on Wednesday after a company executive reported to a government [.

Moderna Vaccine Optimism Could Drive Biotech ETFs

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.

How Will Biotech ETFs React to Q2 Earnings Release?

Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.

Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain

The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.

Biotech ETFs to Gain on Coronavirus Vaccine Progress

Moderna

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating optimism for a swifter economic recovery. Futures on the Dow Jones Industrial Average popped 300 points, while the S&P 500 futures and the Nasdaq 100 [.

Moderna Study Sends Biotech ETFs And Stock Futures Surging

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

Virtus LifeSci Biotech Clinical Trials ETF

With a slew of news to start off the month and quarter, biotech equities and ETFs are moving higher on Wednesday with optimism over developments on the coronavirus vaccine front. The Dow Jones Industrial Average has rallied slightly amid the news, up 0.21%, while the S&P 500 gained 0.63% and the Nasdaq Composite climbed 85%.

Biotech ETFs Gain Amid Vaccine Optimism

In a sea of red stocks on Wednesday, as fear grips markets due to another spike in coronavirus cases throughout the country, Gilead Sciences is one of the few bright spots in the stock market.

Could Gilead News Be Good For Biotech ETFs?

In the continuing quest to find a vaccine for the coronavirus, the World Health Organization announced Wednesday it is dropping hydroxychloroquine, the malaria drug backed by President Trump, who claims it has helped him, from its global study that examines potential treatments for Covid-19. The WHO decided to terminate the trial following another separate trial that [.

News for VanEck Vectors Biotech ETF ETF (BBH)